IL-6 can also be used as a parameter of drug efficacy in the treatment of HCC, as already carried out in a study on antineoplastic treatment with atezolizumab plus bevacizumab carried out recently.85 This evidence concerns the gene IL6 and hepatocellular carcinoma.